Advertisement.

CPRX Projected Dividend Yield

Catalyst Pharmaceuticals Inc ( NASDAQ : CPRX )

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class medicines for rare and difficult-to-treat diseases. Its flagship product, FIRDAPSE (amifampridine) tablets, is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and children aged six to seventeen. The company also markets FYCOMPA (perampanel) CIII for treating focal onset seizures and primary generalized tonic-clonic seizures in people with epilepsy. Additionally, its portfolio includes AGAMREE (vamorolone), an oral suspension for treating Duchenne Muscular Dystrophy (DMD), which is a corticosteroid treatment for DMD patients.

21 YEAR PERFORMANCE RESULTS

CPRX Dividend History Detail
CPRX Dividend News
CPRX Competitors News

# of Shares: 0

Closing Price: 24.11

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000